Tela Bio Announced Sale Of Distribution Rights Related To NIVIS Fibrillar Collagen Pack To MiMedx For Initial $5M Payment And Additional Future Payments Of $3M-$7M Based On Net Sales Of NIVIS Over The Next Two Years

3/20/24 7:13:48 AM ET

$MDXG

$TELA

Biotechnology: Pharmaceutical Preparations

Health Care

Medical/Dental Instruments

Health Care

Get the next $MDXG alert in real time by email

Tela Bio Announced Sale Of Distribution Rights Related To NIVIS Fibrillar Collagen Pack To MiMedx For Initial $5M Payment And Additional Future Payments Of $3M-$7M Based On Net Sales Of NIVIS Over The Next Two Years

Get the next $MDXG alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$MDXG
$TELA

Company	Date	Price Target	Rating	Analyst
MiMedx Group Inc $MDXG	2/23/2026	$10.00	Mkt Outperform	Citizens
TELA Bio Inc. $TELA	3/21/2025	$5.00 → $2.00	Overweight → Neutral	Piper Sandler
MiMedx Group Inc $MDXG	7/2/2024	$11.00	Overweight	Cantor Fitzgerald
MiMedx Group Inc $MDXG	3/7/2024	$12.00	Buy	Lake Street
MiMedx Group Inc $MDXG	10/27/2023	$12.00	Buy	Craig Hallum
MiMedx Group Inc $MDXG	10/13/2022	$7.00	Buy	Mizuho
TELA Bio Inc. $TELA	5/31/2022	$17.00	Buy	Lake Street
MiMedx Group Inc $MDXG	9/14/2021	$20.00 → $8.50	Buy	HC Wainwright & Co.

More analyst ratings

Tela Bio Announced Sale Of Distribution Rights Related To NIVIS Fibrillar Collagen Pack To MiMedx For Initial $5M Payment And Additional Future Payments Of $3M-$7M Based On Net Sales Of NIVIS Over The Next Two Years

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MDXG
$TELA

Tela Bio Announced Sale Of Distribution Rights Related To NIVIS Fibrillar Collagen Pack To MiMedx For Initial $5M Payment And Additional Future Payments Of $3M-$7M Based On Net Sales Of NIVIS Over The Next Two Years

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MDXG
$TELA

$MDXG
$TELA
Analyst Ratings

Citizens initiated coverage on MiMedx Group with a new price target

TELA Bio downgraded by Piper Sandler with a new price target

Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

$MDXG
$TELA
Press Releases

MIMEDX Announces Restructuring and Cost Reduction Initiative

MIMEDX to Sponsor Leading Advanced Wound Care Conferences

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

$MDXG
$TELA
SEC Filings

$MDXG
$TELA
Insider Trading

$MDXG
$TELA
Insider Purchases

MiMedx Group Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-8 filed by TELA Bio Inc.

SEC Form 10-K filed by TELA Bio Inc.

General Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 20,245 shares, decreasing direct ownership by 4% to 543,195 units (SEC Form 4)

Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 6,762 shares, decreasing direct ownership by 2% to 329,450 units (SEC Form 4)

Chief Commercial Officer Maersk-Moller Kimberly exercised 42,845 shares at a strike of $4.50 and covered exercise/tax liability with 21,270 shares, increasing direct ownership by 7% to 336,212 units (SEC Form 4)

Large owner Ew Healthcare Partners Fund 2, L.P. bought $4,000,440 worth of shares (3,604,000 units at $1.11), increasing direct ownership by 88% to 7,714,709 units (SEC Form 4)

Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

$MDXG
$TELA
Financials

MIMEDX Announces Restructuring and Cost Reduction Initiative

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results

$MDXG
$TELA
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

SEC Form SC 13G filed by MiMedx Group Inc

$MDXG
$TELA
Leadership Updates

TELA Bio Appoints William Plovanic to Board of Directors

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

TELA Bio Appoints Jeffrey Blizard as President

Tela Bio Announced Sale Of Distribution Rights Related To NIVIS Fibrillar Collagen Pack To MiMedx For Initial $5M Payment And Additional Future Payments Of $3M-$7M Based On Net Sales Of NIVIS Over The Next Two Years

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MDXG$TELA

Tela Bio Announced Sale Of Distribution Rights Related To NIVIS Fibrillar Collagen Pack To MiMedx For Initial $5M Payment And Additional Future Payments Of $3M-$7M Based On Net Sales Of NIVIS Over The Next Two Years

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MDXG$TELA

$MDXG$TELA Analyst Ratings

Citizens initiated coverage on MiMedx Group with a new price target

TELA Bio downgraded by Piper Sandler with a new price target

Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

$MDXG$TELA Press Releases

MIMEDX Announces Restructuring and Cost Reduction Initiative

MIMEDX to Sponsor Leading Advanced Wound Care Conferences

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

$MDXG$TELA SEC Filings

$MDXG$TELA Insider Trading

$MDXG$TELA Insider Purchases

MiMedx Group Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-8 filed by TELA Bio Inc.

SEC Form 10-K filed by TELA Bio Inc.

General Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 20,245 shares, decreasing direct ownership by 4% to 543,195 units (SEC Form 4)

Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 6,762 shares, decreasing direct ownership by 2% to 329,450 units (SEC Form 4)

Chief Commercial Officer Maersk-Moller Kimberly exercised 42,845 shares at a strike of $4.50 and covered exercise/tax liability with 21,270 shares, increasing direct ownership by 7% to 336,212 units (SEC Form 4)

Large owner Ew Healthcare Partners Fund 2, L.P. bought $4,000,440 worth of shares (3,604,000 units at $1.11), increasing direct ownership by 88% to 7,714,709 units (SEC Form 4)

Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

$MDXG$TELA Financials

MIMEDX Announces Restructuring and Cost Reduction Initiative

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results

$MDXG$TELA Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

SEC Form SC 13G filed by MiMedx Group Inc

$MDXG$TELA Leadership Updates

TELA Bio Appoints William Plovanic to Board of Directors

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

TELA Bio Appoints Jeffrey Blizard as President

Recent Analyst Ratings for
$MDXG
$TELA

Recent Analyst Ratings for
$MDXG
$TELA

$MDXG
$TELA
Analyst Ratings

$MDXG
$TELA
Press Releases

$MDXG
$TELA
SEC Filings

$MDXG
$TELA
Insider Trading

$MDXG
$TELA
Insider Purchases

$MDXG
$TELA
Financials

$MDXG
$TELA
Large Ownership Changes

$MDXG
$TELA
Leadership Updates